These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25946708)

  • 1. Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group.
    Getz KD; Li Y; Alonzo TA; Hall M; Gerbing RB; Sung L; Huang YS; Arnold S; Seif AE; Miller TP; Bagatell R; Fisher BT; Adamson PC; Gamis A; Keren R; Aplenc R
    Pediatr Blood Cancer; 2015 Oct; 62(10):1775-81. PubMed ID: 25946708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
    Gamis AS; Alonzo TA; Meshinchi S; Sung L; Gerbing RB; Raimondi SC; Hirsch BA; Kahwash SB; Heerema-McKenney A; Winter L; Glick K; Davies SM; Byron P; Smith FO; Aplenc R
    J Clin Oncol; 2014 Sep; 32(27):3021-32. PubMed ID: 25092781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group.
    Miller TP; Troxel AB; Li Y; Huang YS; Alonzo TA; Gerbing RB; Hall M; Torp K; Fisher BT; Bagatell R; Seif AE; Sung L; Gamis A; Rubin D; Luger S; Aplenc R
    Pediatr Blood Cancer; 2015 Jul; 62(7):1184-9. PubMed ID: 25760019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
    Cooper TM; Franklin J; Gerbing RB; Alonzo TA; Hurwitz C; Raimondi SC; Hirsch B; Smith FO; Mathew P; Arceci RJ; Feusner J; Iannone R; Lavey RS; Meshinchi S; Gamis A
    Cancer; 2012 Feb; 118(3):761-9. PubMed ID: 21766293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
    Lamba JK; Chauhan L; Shin M; Loken MR; Pollard JA; Wang YC; Ries RE; Aplenc R; Hirsch BA; Raimondi SC; Walter RB; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S
    J Clin Oncol; 2017 Aug; 35(23):2674-2682. PubMed ID: 28644774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.
    Pollard JA; Loken M; Gerbing RB; Raimondi SC; Hirsch BA; Aplenc R; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S
    J Clin Oncol; 2016 Mar; 34(7):747-55. PubMed ID: 26786921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
    Aplenc R; Alonzo TA; Gerbing RB; Lange BJ; Hurwitz CA; Wells RJ; Bernstein I; Buckley P; Krimmel K; Smith FO; Sievers EL; Arceci RJ;
    J Clin Oncol; 2008 May; 26(14):2390-3295. PubMed ID: 18467731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
    Alexander TB; Wang L; Inaba H; Triplett BM; Pounds S; Ribeiro RC; Pui CH; Rubnitz JE
    Cancer; 2017 Oct; 123(19):3791-3798. PubMed ID: 28556917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia.
    Miller TP; Li Y; Kavcic M; Troxel AB; Huang YS; Sung L; Alonzo TA; Gerbing R; Hall M; Daves MH; Horton TM; Pulsipher MA; Pollard JA; Bagatell R; Seif AE; Fisher BT; Luger S; Gamis AS; Adamson PC; Aplenc R
    J Clin Oncol; 2016 May; 34(13):1537-43. PubMed ID: 26884558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
    Elsayed AH; Cao X; Mitra AK; Wu H; Raimondi S; Cogle C; Al-Mansour Z; Ribeiro RC; Gamis A; Kolb EA; Aplenc R; Alonzo TA; Meshinchi S; Rubnitz J; Pounds S; Lamba JK
    J Clin Oncol; 2022 Mar; 40(7):772-783. PubMed ID: 34990262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232.
    DiNofia AM; Seif AE; Devidas M; Li Y; Hall M; Huang YV; Cahen V; Hunger SP; Winick NJ; Carroll WL; Fisher BT; Larsen EC; Aplenc R
    Cancer Med; 2018 Jan; 7(1):3-12. PubMed ID: 29274118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.
    Vaughn JE; Othus M; Powell MA; Gardner KM; Rizzuto DL; Hendrie PC; Becker PS; Pottinger PS; Estey EH; Walter RB
    JAMA Oncol; 2015 Nov; 1(8):1120-7. PubMed ID: 26355382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
    Burnett AK; Hills RK; Milligan D; Kjeldsen L; Kell J; Russell NH; Yin JA; Hunter A; Goldstone AH; Wheatley K
    J Clin Oncol; 2011 Feb; 29(4):369-77. PubMed ID: 21172891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens.
    Clavio M; Quintino S; Masoudi B; Carrara S; Cerri R; Pierri I; Canepa L; Miglino M; Muner P; Damasio E; Gobbi M
    J Exp Clin Cancer Res; 2001 Jun; 20(2):165-73. PubMed ID: 11484970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).
    Amadori S; Suciu S; Stasi R; Salih HR; Selleslag D; Muus P; De Fabritiis P; Venditti A; Ho AD; Lübbert M; Thomas X; Latagliata R; Halkes CJ; Falzetti F; Magro D; Guimaraes JE; Berneman Z; Specchia G; Karrasch M; Fazi P; Vignetti M; Willemze R; de Witte T; Marie JP
    J Clin Oncol; 2013 Dec; 31(35):4424-30. PubMed ID: 24127442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia.
    Getz KD; Miller TP; Seif AE; Li Y; Huang YS; Bagatell R; Fisher BT; Aplenc R
    Cancer Med; 2015 Sep; 4(9):1356-64. PubMed ID: 26105201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
    Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
    Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
    J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
    Laszlo GS; Alonzo TA; Gudgeon CJ; Harrington KH; Kentsis A; Gerbing RB; Wang YC; Ries RE; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S; Walter RB
    J Hematol Oncol; 2015 Oct; 8():115. PubMed ID: 26487643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.